{"links":{"html":"https://www.erudio.com/reports/panku-breast02-nct06382142","json":"https://www.erudio.com/reports/panku-breast02-nct06382142.json","markdown":"https://www.erudio.com/reports/panku-breast02-nct06382142.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"panku-breast02-06382142"}},"request":"https://www.erudio.com/contact?report=panku-breast02-06382142"},"offer":{"cited_commentary_sources":28,"verified_hcp_statements":125,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":12,"optional":true,"price_per_verified_person_usd":15,"price_usd":180,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"panku-breast02-nct06382142"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=panku-breast02-06382142","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/panku-breast02-nct06382142","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-01T16:30:50.297807Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":23,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":19,"title":"Primary endpoint: Progression-free survival (PFS)"},{"claim_count":26,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":19,"title":"Primary endpoint: Overall survival (OS)"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":15,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":11,"title":"Population and setting"},{"claim_count":13,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":12,"title":"The comparison"},{"claim_count":19,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":10,"title":"Safety and tolerability"},{"claim_count":13,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":9,"title":"Design and conduct"},{"claim_count":11,"coverage":"discussed","id":"A1","source_count":6,"title":"ADC sequencing and resistance at the post-taxane decision"},{"claim_count":16,"coverage":"discussed","id":"A2","source_count":9,"title":"Geographic applicability, international development, regulation and access"},{"claim_count":25,"coverage":"discussed","id":"A3","source_count":10,"title":"Bispecific design, target selection and proposed biological advantages"},{"claim_count":28,"coverage":"discussed","id":"A4","source_count":18,"title":"Clinical significance, prospective treatment role and communication of enthusiasm"},{"claim_count":3,"coverage":"discussed","id":"A5","source_count":2,"title":"AI forecasts and retrospective model-performance commentary"}],"counts":{"cited_sources":28,"claims_by_expression_type":{"comparison":1,"interpretation":29,"opinion":49,"primary_context":2,"question":5,"restatement":23,"uncertainty":10,"unspecified":6},"claims_by_kind":{"interpretation":2,"limitation":3,"source_observation":120},"clinician_statements":34,"evidence_units":91,"findings":7,"organisational_accounts":3,"people_cited":15,"people_identity_verified":12,"people_total":16,"screened_sources":50,"verified_claims":125},"findings_index":[{"id":"F1","structure":{"claims":12,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":4,"views":7},"has_counterview":true,"limitations":3,"links":{"context":1,"support":12},"ma_question":true,"named_voices":6,"passages":9,"sources":6,"sources_by_kind":{"commentary":4,"media":2}},"title":"Substantial toxicity makes supportive care central to the benefit–risk discussion"},{"id":"F2","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":0,"views":4},"has_counterview":true,"limitations":3,"links":{"context":1,"support":8},"ma_question":true,"named_voices":4,"passages":6,"sources":4,"sources_by_kind":{"commentary":3,"media":1}},"title":"Activity after a prior topoisomerase I ADC remains an unanswered treatment-sequencing question"},{"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":10},"has_counterview":true,"limitations":3,"links":{"context":3,"support":12},"ma_question":true,"named_voices":6,"passages":11,"sources":6,"sources_by_kind":{"commentary":5,"media":1}},"title":"Strong efficacy enthusiasm coexists with an explicitly incremental view of survival progress"},{"id":"F4","structure":{"claims":1,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":1},"has_counterview":true,"limitations":3,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"One favorable assessment specifically challenges the heterogeneous chemotherapy control"},{"id":"F5","structure":{"claims":8,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":6},"has_counterview":true,"limitations":3,"links":{"context":1,"support":9},"ma_question":true,"named_voices":5,"passages":9,"sources":5,"sources_by_kind":{"commentary":3,"media":2}},"title":"China-only evidence prompts development optimism and a call for broader applicability"},{"id":"F6","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":1,"views":7},"has_counterview":true,"limitations":3,"links":{"context":3,"support":11},"ma_question":true,"named_voices":5,"passages":12,"sources":5,"sources_by_kind":{"commentary":2,"media":3}},"title":"Bispecific targeting is attractive because of heterogeneity, but its proposed advantages remain hypotheses"},{"id":"F7","structure":{"claims":11,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":2,"views":6},"has_counterview":true,"limitations":4,"links":{"context":0,"support":12},"ma_question":true,"named_voices":4,"passages":8,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"A possible future option is not the same as an established standard or an available treatment"}],"medical_affairs_question":"For patients reaching this post-taxane decision after a prior ADC, what evidence would justify choosing iza-bren, and under what supportive-care and access conditions?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Supportive care is part of the benefit–risk interpretation"},{"id":"section-2","level":2,"title":"The unresolved sequence is iza-bren after another ADC"},{"id":"section-3","level":2,"title":"Efficacy enthusiasm is strong, but survival progress is still described as incremental"},{"id":"section-4","level":2,"title":"Comparator selection is a distinct methodological reservation"},{"id":"section-5","level":2,"title":"International development optimism does not establish global applicability or access"},{"id":"section-6","level":2,"title":"Dual targeting offers a rationale, not a demonstrated solution to resistance"},{"id":"section-7","level":2,"title":"Prospective treatment roles must remain distinct from established status"},{"id":"section-8","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":4},{"id":"F7","shared_claims":1}],"id":"T1","label":"Primary endpoint: Progression-free survival (PFS)"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":6},{"id":"F7","shared_claims":1}],"id":"T2","label":"Primary endpoint: Overall survival (OS)"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":4}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":11},{"id":"F5","shared_claims":1},{"id":"F7","shared_claims":4}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1},{"id":"F7","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-01T16:30:50.297807Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-01T16:42:57Z","record_hash":"70dddaf40b277be45e52dbc93ba31db3ede9ba7881f30f3597893ea92584598b","release_hash":"d66ded642427f6853062e4a9fda64eddeb0de2d616ff84cf3f9497addf5b3ca3","report_id":"erudio-nct06382142","run_id":"1d726372-4177-400b-ac9d-d460a6de67b0","schema_version":"5.0","slug":"panku-breast02-06382142","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"PANKU-Breast02 compares BL-B01D1 with chemotherapy after taxane failure in unresectable locally advanced or metastatic triple-negative breast cancer; the benefit–risk discussion centers on toxicity and supportive care. The report cites seven physicians, six of them medical oncologists. Beyond applicability outside China, the open question is what evidence, supportive care and access would justify BL-B01D1 after a prior topoisomerase I antibody–drug conjugate. The sources reviewed for this edition place PANKU-Breast02 results at ASCO 2026.","meta_description":"50 sources screened · 125 verified statements (34 from clinicians verified by NPI or staff page) from 28 sources · 7 findings. Updated Nov 1, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-b1bdbd2c472e429693b2"],"id":"F7","paraphrase":"An X-thread post asks which antibody–drug conjugate should follow taxane-containing therapy in metastatic triple-negative breast cancer, and for which patients.","publication_caveats":{"reason":"Publication-specific caveats are not specified in the sources reviewed for this edition.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-06-11","title":"A possible future option is not the same as an established standard or an available treatment"}]},"publication":{"approved_at":"2026-11-01T16:42:57Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":50},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on standard-of-care adoption in pretreated metastatic triple-negative breast cancer.","Not yet captured in this edition: a view on treatment choice and tolerability in previously treated advanced triple-negative breast cancer.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The sources reviewed for this edition are not a representative sample of HCP opinion. Multiple posts, clips and formats can repeat the same discussion rather than provide independent agreement.","Some potentially relevant passages were not fully assessed, and discussion that does not use familiar study names or identifiers may be absent. Additional qualifications or dissent may therefore be missing.","No protocol or original full trial-results publication was available. Numerical efficacy and safety findings are reported as what the contributors said, not as an independent analysis of the complete dataset.","Several passages cannot be assigned to a named speaker. Clinical roles are not established for every named contributor; source-stated credentials and trial involvement remain descriptions made by those sources.","Organizations, AI-generated forecasts, relayed presentation summaries and reposts must not be counted as additional independent HCP opinions.","Early topline and abstract-based comments reflect the information available in those particular communications. Differences in detail or publication date do not by themselves establish a change of mind.","Reported enrollment figures are inconsistent across posts and, in one post, with the separately listed arm sizes. These figures are not reconciled.","Regulatory information is incomplete. Expected FDA evidence requirements and descriptions of pending access are not formal regulatory decisions or proof of current availability in every location."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":18,"x_video":0,"youtube":7},"by_evidence_role":{"commentary":28},"count":28,"evidence_window":{"end":"2026-09-03","start":"2026-02-26"},"retrieval_snapshot":"2026-11-01T15:40:38.041340Z","timeline":[{"count":2,"week":"2026-W09"},{"count":1,"week":"2026-W13"},{"count":1,"week":"2026-W21"},{"count":1,"week":"2026-W22"},{"count":10,"week":"2026-W23"},{"count":2,"week":"2026-W24"},{"count":1,"week":"2026-W25"},{"count":1,"week":"2026-W26"},{"count":3,"week":"2026-W30"},{"count":1,"week":"2026-W31"},{"count":3,"week":"2026-W34"},{"count":1,"week":"2026-W35"},{"count":1,"week":"2026-W36"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT06382142:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06382142:context","quote_policy":"short_quote_link_out"},{"id":"openfda:7752b084-cdc7-6eac-e294-e45db82c372a:20260831","quote_policy":"short_quote_link_out"},{"id":"openfda:10a70995-e04d-4044-b1dc-c9aa27460397:20240816","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3mfrp5mhvt22e","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-mdlcbvaeudqgcmcai6536voq-3muhid3izxk2n","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tqeem2vohbmovhfmphkgjdtb-3mnczc6insq2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-umyugdennwrxkh5hlz3gdynw-3mo3xdrnyiu2i","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7476132406840774656","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:2f1740","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:b01439","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027068118338588761:596510ea-a7c3-4c52-8249-410abcbddcfc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027070038394487286:b2dd722f-364b-4ba1-8111-9344758632b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027278293872111939:a164c810-90ca-47e4-ace4-201e4d455e69","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2027409624522264718:c9460df0-6519-44bd-a839-2fe7c7b02928","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037336629728379283:5a9f81e5-dcfe-412e-b9f8-cba73aab48b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2056716093738389862:8180ff4a-979f-43cf-a7c9-216ed9d478a2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2058546493343072365:12f9f3df-c3d5-4f85-aca1-1f07c18fd642","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2060122751156007216:f4915985-0dd9-49c7-bbb1-206f3ee44ab3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061818067269878181:388536ea-0654-4ec2-b948-947b60678f42","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061838848569507997:85b9fe20-05ae-40e0-a2bd-b2658f1cd02e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061839394084888912:9be42e93-0404-4052-88cc-b9c46dcf34b2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061839889843323182:d7ba2569-f9bd-4a03-a131-ba1899ff26a1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061840116985766369:3a389714-9738-4d83-9bff-0e68403fe143","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061841066433618023:6faa8e9a-b6be-43bb-94ab-da00ed90e3d6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061841960583766489:a822fd05-75f6-47c0-85b4-48beae8eb973","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061847477519585557:9989c717-59d5-498b-b2c3-425086050cd7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061892208417021989:b5d4b669-9d5a-4859-a986-415aa0f0cfb9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061896485927559234:9a2420dc-760f-4b91-a30e-c70df07e7e2c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062206790012739919:4019fa1b-f9de-43db-84ab-80a35dc0eeed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062210198148714803:93ded51a-8bdb-4519-ac34-d215d0f68bfc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062385281194717635:1a50bcba-93ef-464f-bfa0-f4d523f04d4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062533856713195993:57937dbf-7b07-4d9a-b0f9-ed296b0d7375","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2062620908053844263:59bc553b-6ae7-4800-aeae-53edeb01da06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2063223261576699978:67cafa57-b156-4366-8fb1-2441e627b451","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064018623661035876:e964f33c-71d0-489a-8560-7365c0dc9eda","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2064996071286149391:ad771663-51bb-4be6-a720-97e6685cc82e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067067660890714355:cd511c04-2f49-4250-87d7-08ba637220db","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067068103574323295:5fce9d35-5179-4fdf-a466-bd623c460e40","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067068436350406890:8d16c02a-e2c8-4838-8b62-5023ce1e6ca1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2067232040437887014:96d37d60-5e4e-4a50-98bb-c78c356f623d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2070560399741657237:11f0b0bf-61a8-453c-849c-2d92da3c6781","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2077046714301559261:fcf6e4ac-d54b-46a0-a3dc-a6f08a8283e3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079556886924312614:e15b72f0-14b6-4788-bdd3-e7c7db40708c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2079567204291338386:99c14700-c3a3-430f-ba4a-f8054a6d7fdf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2094427739654627404:bfe43065-b07d-444c-ab01-6c69f8896ae9","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BZC5_C3KyjE","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SCnsK__7FwI","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:bIbDHoaWczc","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:d4GPEXwqWdQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:mu9oDRU_AzM","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:tk4otW66tAk","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vBb52e5G0fQ","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:x0xOtk_Egds","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":4,"linkedin_post":1,"other":0,"podcast":2,"publication":0,"registry":0,"regulatory":0,"x_thread":35,"x_video":0,"youtube":8},"by_evidence_role":{"commentary":50},"count":50,"evidence_window":{"end":"2026-10-20","start":"2026-02-26"},"retrieval_snapshot":"2026-11-01T15:40:38.041340Z","timeline":[{"count":6,"week":"2026-W09"},{"count":1,"week":"2026-W13"},{"count":2,"week":"2026-W21"},{"count":2,"week":"2026-W22"},{"count":18,"week":"2026-W23"},{"count":3,"week":"2026-W24"},{"count":4,"week":"2026-W25"},{"count":2,"week":"2026-W26"},{"count":1,"week":"2026-W29"},{"count":3,"week":"2026-W30"},{"count":1,"week":"2026-W31"},{"count":3,"week":"2026-W34"},{"count":1,"week":"2026-W35"},{"count":3,"week":"2026-W36"},{"count":1,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: bl-b01d1","status":"unmapped"},{"brand_names":["Halaven"],"label":"eribulin","slug":"eribulin"},{"brand_names":["Navelbine"],"label":"vinorelbine","slug":"vinorelbine"},{"brand_names":["Gemzar"],"label":"gemcitabine","slug":"gemcitabine"},{"brand_names":["Xeloda"],"label":"capecitabine","slug":"capecitabine"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Triple-negative breast cancer","slug":"triple-negative-breast-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"PANKU-Breast02","aliases":["PANKU-Breast02","A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)","A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure"],"brief_title":"A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)","collaborators":["Baili-Bio (Chengdu) Pharmaceutical Co., Ltd."],"conditions":["Triple-Negative Breast Cancer"],"display_condition":"unresectable locally advanced or metastatic triple-negative breast cancer","display_interventions":[["izalontamab brengitecan (BL-B01D1)"]],"enrollment":{"count":418,"type":"ACTUAL"},"interventions":[{"name":"BL-B01D1","synonyms":["iza-bren","izalontamab brengitecan","BMS-986507"],"type":"DRUG"},{"name":"Eribulin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Vinorelbine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Gemcitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Capecitabine","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06382142","official_title":"A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer After Taxane Failure","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2026-01-13","type":"ACTUAL"},"primary_endpoints":[{"description":"Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.","measure":"Progression-free survival (PFS)","timeFrame":"Up to approximately 24 months"},{"description":"Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.","measure":"Overall survival (OS)","timeFrame":"Up to approximately 24 months"}],"registered_date":{"date":"2024-04-24","type":"ACTUAL"},"registry_last_updated":"2026-07-23","registry_url":"https://clinicaltrials.gov/study/NCT06382142","short_name":"PANKU-Breast02","short_name_basis":"canonical_name","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","start_date":{"date":"2024-06-21","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"BL-B01D1-307","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}